X. Yu

发表

141 EXTENDED TREATMENT DURATION IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY

M. Buti, C. Sarrazin, A. Horban, 2009 .

OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

P. Janne, D. Camidge, M. Millward, 2021, Journal of Thoracic Oncology.

Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

M. Diago, E. Zuckerman, A. Craxì, 2012, Journal of viral hepatitis.

1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC

Yunpeng Liu, Dong Wang, Juxian Wang, 2020 .